Lakewood-Amedex Biotherapeutics Inc.
No enriched coverage for $LABT in the last 7 days.
No SEC Form 4 filings for $LABT in the last 30 days.
A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
Lakewood-Amedex Biotherapeutics (LABT) said it presented new data on its antimicrobial candidate Nu-3 for infected diabetic foot ulcers. The company reported a high barrier to resistance in serial passage tests and broad in vitro activity against multiple resistant bacteria mechanisms. LABT linked the findings to the National Action Plan discussed at a June 2026 PACCARB meeting. LABT closed at $1.86.
Lakewood-Amedex Biotherapeutics (LABT) shares rose about 108% on Wednesday after the company highlighted new data for its lead antimicrobial candidate, Nu-3, saying it showed a high barrier to bacterial resistance. The stock was quoted around $3.86 on Nasdaq, up about $2.00, after opening at $6.50.
Recent LABT coverage spans technology and market movers.
Clinical update for Nu-3 (Phase 2-ready) is a fundamental catalyst that can re-rate risk and timelines for LABT.
New preclinical resistance and in vitro breadth claims for Nu-3 could improve perceived differentiation, but no clinical readout is provided.
The article attributes the sharp rally to newly highlighted Nu-3 resistance-barrier data, which can shift perceived clinical and commercial viability.
Preclinical safety and dose selection for Nu-3 de-risks early clinical execution and supports trial readiness for Phase 2a in infected diabetic foot ulcers.
alphai scores every news story that mentions LABT with an AI model for sentiment and relevance, and aggregates insider trades from Lakewood-Amedex Biotherapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
3 min readLakewood-Amedex Biotherapeutics (LABT) said it presented new data on its antimicrobial candidate Nu-3 for infected diabetic foot ulcers. The company reported a high barrier to resistance in serial passage tests and broad in vitro activity against multiple resistant bacteria mechanisms. LABT linked the findings to the National Action Plan discussed at a June 2026 PACCARB meeting. LABT closed at $1.86.
3 min readLakewood-Amedex Biotherapeutics (LABT) shares rose about 108% on Wednesday after the company highlighted new data for its lead antimicrobial candidate, Nu-3, saying it showed a high barrier to bacterial resistance. The stock was quoted around $3.86 on Nasdaq, up about $2.00, after opening at $6.50.
1 min readLakewood-Amedex Biotherapeutics (NASDAQ: LABT) said preclinical safety data for its Nu-3 topical gel supported dose selection for an upcoming Phase 2a trial in infected diabetic foot ulcers. The company reported Nu-3 was well tolerated in an FDA-required safety study at higher doses, with low systemic exposure and no wound-healing inhibition. Planned gel concentrations are 2%, 5%, and 10%.
3 min read
